Immobilized HVEM/TNFRSF14, Human (Cat. No. UA010658) at 2.0μg/mL (100μL/well) can bind BTLA Fc Chimera, Human
(Cat. No. UA010754) with EC50 of 1.86-2.21 μg/mL.
Species | Human |
Synonyms | BTLA,CD272 |
Accession | Q7Z6A9-1 |
Amino Acid Sequence | Lys31-Thr134, with C-terminal Fc |
Expression System | HEK293 |
Molecular Weight | 45-55kDa (Reducing) |
Purity | >95% by SDS-PAGE |
Endotoxin | <0.1EU/μg |
Conjugation | Unconjugated |
Tag | Human Fc Tag |
Physical Appearance | Lyophilized Powder |
Storage Buffer | PBS, pH7.4. |
Reconstitution | Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation. |
Stability & Storage | · 12 months from date of receipt, lyophilized powder stored at -20 to -80℃. · 3 months, -20 to -80℃ under sterile conditions after reconstitution. · 1 week, 2 to 8℃ under sterile conditions after reconstitution. · Please avoid repeated freeze-thaw cycles. |
Reference |
1.Fourcade J, et al. (2012) CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1. Cancer Res. 72(4):887-96. 2.Kojima R, et al. (2011) Molecular basis for herpesvirus entry mediator recognition by the human immune inhibitory receptor CD160 and its relationship to the cosignaling molecules BTLA and LIGHT. J Mol Biol. 413(4):762-72. |
B-and T-lymphocyte attenuator (BTLA) is also known as B-and T-lymphocyte-associated protein, CD antigen CD272. BTLA is a inhibitory molecule which belongs to the Ig superfamily that attenuates BCR and TCR-mediated signaling, and thereby functions as a negative regulator of lymphocyte activation. BTLA contains one Ig-like V-type (immunoglobulin-like) domain. As a lymphocyte inhibitory receptor, BTLA / CD272 inhibits lymphocytes during immune response. BTLA is not expressed by naive T cells, but it is induced during activation and remains expressed on T helper type 1 (T(H)1) but not T(H)2 cells.
Immobilized HVEM/TNFRSF14, Human (Cat. No. UA010658) at 2.0μg/mL (100μL/well) can bind BTLA Fc Chimera, Human
(Cat. No. UA010754) with EC50 of 1.86-2.21 μg/mL.
1μg (R: reducing condition, N: non-reducing condition).